Navigation Links
Genzyme and Bayer Schering Pharma AG, Germany Announce Start of Phase 3 Program with Alemtuzumab for Treatment of Multiple Sclerosis
Date:9/26/2007

ical centers throughout North America, Australia, Latin America, and Europe, and will again compare alemtuzumab-treated patients to Rebif-treated patients according to two co-primary endpoints: the time to sustained accumulation of disability, and the annualized relapse rate. Alemtuzumab will be dosed at 12 mg/day for five days by daily IV infusion, with a second dosing 12 months later of 12 mg/day for three days. All patients will be followed from their entry into the trial until two years from the date that the last patient is randomized to treatment. Alemtuzumab-treated patients will continue to have safety evaluations for at least three years after the last course of treatment. The companies anticipate filing for marketing approval of alemtuzumab for the treatment of MS in 2011.

Alemtuzumab is an investigational drug for the treatment of MS and must not be used outside of a formal clinical trial setting in MS patients. Physicians or patients seeking additional information about the CARE-MS I trial should contact Genzyme Medical Information at 1-800-745-4447, option 2 in the United States, + 31 35 6991499 in Europe, or visit http://www.clinicaltrials.gov.

About Multiple Sclerosis

Multiple Sclerosis (MS) is a chronic disease of the central nervous system (CNS) in which the immune system can attack the brain and spinal cord. The disease causes a wide range of symptoms including fatigue, difficulty walking, numbness, and vision problems, and can progress to cause severe disability. Relapsing-remitting MS is the most common form of this disease.

About Alemtuzumab

Alemtuzumab is licensed in the United States as a single agent for the treatment of B-cell chronic lymphocytic leukemia (B-CLL), and outside of the U.S. for the treatment of B-CLL in patients who have been treated with alkylating agents and who have failed fludarabine therapy. The product was launched in its oncology indi
'/>"/>

SOURCE Genzyme Corporation; Bayer Schering Pharma AG
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
2. Genzyme Announces Results of Clinical Trial of Hylastan
3. Genzyme Announces Results of Clinical Trials Investigating Powder Form of Sevelamer Carbonate
4. Genzyme Announces Results of Clinical Trials Investigating Powder Form of Sevelamer Carbonate
5. Genzyme and Bayer HealthCare Announce Detailed Interim Two-Year Alemtuzumab in Multiple Sclerosis Data Presented at AAN
6. Genzyme Announces Successful Completion of Study Investigating Sevelamer Carbonate in Patients With Chronic Kidney Disease
7. Schering-Plough Announces Hepatitis C Data Presentations at Digestive Disease Week (DDW) 2007 Annual Meeting
8. Schering-Plough Addresses Major Milestones and Challenges in Treatment of Patients With Chronic Hepatitis C
9. Schering-Plough Announces Presentation of Phase II Trial Results for Novel Oral Thrombin Receptor Antagonist at the 2007 Annual Meeting of The American College of Cardiology/i2 Summit
10. Sygnis Pharma AG announces date for presentation of clinical results
11. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... 2015 PTC Therapeutics, Inc. (NASDAQ: PTCT ... results for the second quarter ending June 30, 2015. ... across the organization.  We are excited to be near ... trial ever conducted with topline results expected in the ... Officer, PTC Therapeutics, Inc. "Translarna is now commercially available ...
(Date:7/30/2015)... 2015  Cleveland Clinic President Wael Barsoum , ... month that industry is compelled to adopt declining reimbursements ... efficiencies—and develop the transformational innovations -- required to thrive ... preceded by Doug Kohrs , past President and ... stressed that industry must add "episode of care," also ...
(Date:7/30/2015)... July 30, 2015 Future Market ... titled, "Continuous Glucose Monitoring Systems Market: Global Industry Analysis ... report, the global continuous glucose monitoring systems market was ... expected to reach US$ 788.4 Mn by 2020, registering ... to 2020. Global continuous glucose monitoring systems ...
Breaking Medicine Technology:PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 2PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 3PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 4PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 5PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 6PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 7PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 8PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 9PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 10Orthopaedic Surgery Reimbursement Shifts to Episode of Care 2Global Continuous Glucose Monitoring (CGM) Systems Market: Transmitters and Monitors Most Dominant Segment, Says Future Market Insights 2Global Continuous Glucose Monitoring (CGM) Systems Market: Transmitters and Monitors Most Dominant Segment, Says Future Market Insights 3Global Continuous Glucose Monitoring (CGM) Systems Market: Transmitters and Monitors Most Dominant Segment, Says Future Market Insights 4
... issued the following update regarding the voluntary recall of AVEA® ... this action as a Class I recall. ... by the company and CareFusion is actively remediating the hardware ... parts manufactured between March 1, 2009 and June 30, 2011 ...
... Valeant Pharmaceuticals International, Inc. (NYSE: VRX ... the company completed its previously announced acquisition of iNova, ... BofA Merrill Lynch and Baker & McKenzie ... About Valeant Pharmaceuticals International, Inc. ...
Cached Medicine Technology:CareFusion Provides Update on Previously Announced Ventilator Recall 2
(Date:7/31/2015)... ... ... Like nearly every other form of surgery, it shouldn't come as a surprise ... intrusive and painful. Leading these advances in the United States has been Dr. ... the only doctor in the United States who is qualified to practice, and is ...
(Date:7/31/2015)... ... , ... The Heart Fit Clinic has increased a patient's fitness level 60 ... 150 beats versus 100 beats, this is a big deal," says Diamond Fernandes, director ... to patients with heart disease," he adds. People with angina are able to do ...
(Date:7/31/2015)... ... July 31, 2015 , ... Burnaby sports physiotherapy clinic, Absolute ... understanding and treatment of ankle sprains. A common sports injury, ankle sprains are ... dangerous if the condition augments and causes more disruption. Absolute PhysioCare’s blog discusses ...
(Date:7/31/2015)... ... ... Awarded to only the Top 10 hair transplant practices in the United ... recipients of the Center of Clinical Excellence for ARTAS Robotic Hair Transplantation . ... science of hair transplant. , Parsa Mohebi Hair Restoration is known worldwide for their ...
(Date:7/31/2015)... ... ... Down is a reputable source of authentic USA vs. Australia tickets at Ford ... National Team in conjunction with their Victory Tour to celebrate winning the 2015 Women's World ... team was awarded the Golden Ball as the best player of the 2015 Women's World ...
Breaking Medicine News(10 mins):Health News:Loria Medical Penile Enlargement Center to Expand, Offering Practice Partnership to Doctors 2Health News:Heart Fit Clinic Helps Patient Increase Fitness Level with External Counterpulsation 2Health News:Absolute PhysioCare & Sports Rehab Promotes Understanding & Treatment of Ankle Sprains 2Health News:Prestigious Medical Award Given To Parsa Mohebi Hair Restoration for Excellence in Hair Transplantation 2Health News:Cheap USA vs. Australia Tickets at Ford Field in Detroit, MI: Ticket Down Slashes Ticket Prices for Australia vs. USWNT International Friendly Match at Ford Field 2
... on the onus of improving the treatment for cancer patients, ... a $15 million funding will be instituted. ,The ... the pre-budget statement, will also outline the other medical initiatives ... the projects. Treasurer John Brumby has said that the main ...
... their health care despite the fact that health care ... were the results of a multi-national survey that was ... revealed that United States had spent $6,280 per capital ... industrialized countries. ,US patients reported more diagnostic ...
... as a milestone, researchers at the Wake Forest University in ... conditions and what’s more// have implanted these bladders into seven ... Dr. Anthony Atala has published their experimental study in the ... children in the study were suffering from a birth defect ...
... 4. Women approaching menopause are likely to face depression, says ... aggressive treatment.//, ,Depression is a substantial illness with significant ... problem that can be managed, reports the health portal WebMd. ... the Massachusetts General Hospital studied 460 Boston women aged 36 ...
... that the culling operations in Jalgoan where a fresh outbreak ... B K Wankhade, Regional District Commissioner, Animal Husbandry said that ... outbreak was reported ,500 health workers in 82 ... owners had been compensated to the tune of Rs 1 ...
... state Health Directorate officials have confirmed that there has ... fever in about 29// villages of Nasik district. Around ... have been hospitalized. ,Malegon was the worst ... were sent to the National Institute of Virology (NIV), ...
Cached Medicine News:
ICL manipulator, blunt, forked tip...
ICL manipulator with textured hemi-ball tip...
ICL manipulator with textured micro-ball tip....
0.25 mm diameter textured tip with protective guard....
Medicine Products: